Roche’s cancer immunotherapy Tecentriq (atezolizumab) has received approval in the US for the treatment of a specific form of bladder cancer.
This is the eleventh indication for Tecentriq in the USA, as Roche subsidiary Genentech announced on Friday.
Tecentriq has been approved as a complementary therapy for patients with muscle-invasive bladder cancer (MIBC) after removal of the urinary bladder in whom tests have identified residual molecular disease, according to announcements from Genentech and the US Food and Drug Administration (FDA) on Friday evening.
By combining cancer immunotherapy with state-of-the-art tests, patients who are eligible for treatment can be identified more precisely, according to the Genentech announcement. The FDA’s decision was based on phase III studies that showed a reduction in disease recurrence as well as the risk of death.
Tecentriq is approved for a range of aggressive and difficult-to-treat cancers, including lung cancer, certain types of metastatic urothelial carcinoma and breast cancer. In 2025, the Swiss pharmaceutical company recorded sales of 3.6 billion Swiss francs with Tecentriq.
/tp/AWP/he
WASHINGTON (dpa-AFX)